The Patent Finder

Med-Life Discoveries LP

11 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Aug 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 27, 2027
    The maintenance fee for Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof (US 9,169,280) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
  • 2 fees due Nov 10 to 19, 2027 · next Nov 10

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,993,623Method for Lowering Cholesterol
In force
 · Medium confidence
In forceMedium confidence
US 9,517,222Method for the treatment of senile dementia of the Alzheimer's type
In force
 · USPTO record
In forceUSPTO record
US 10,123,989Method of lowering cholesterol
In force
 · USPTO record
In forceUSPTO record
US 10,697,969Methods for diagnosing a colorectal cancer (CRC) health state or change in CRC health state, or for diagnosing risk of developing CRC or the presence of CRC in a subject
In force
 · USPTO record
In forceUSPTO record
US 8,304,246Methods for the diagnosis of dementia and other neurological disorders
In force
 · USPTO record
In forceUSPTO record
US 10,302,624Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging
In force
 · Medium confidence
In forceMedium confidence
US 10,656,155Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis
In force
 · High confidence
In forceHigh confidence
US 9,034,923Methods for the Treatment of Senile Dementia of the Alzheimer's Type
In force
 · High confidence
In forceHigh confidence
US 9,169,280Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof
In force
 · USPTO record
In forceUSPTO record
US 9,334,235Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
In force
 · USPTO record
In forceUSPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 6 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited